Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Ying Cheng; Yun Fan; Yanqiu Zhao; Dingzhi Huang; Xingya Li; Peng Zhang; Mafei Kang; Nong Yang; Diansheng Zhong; Zhen Wang; Yan Yu; Yu Zhang; Jun Zhao; Tai Qin; Chenqi Chen; Shiangjiin Leaw; Wenjuan Zheng; Yong Song

doi:10.1016/j.jtho.2024.03.008

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial | Litlas